MBX-8025 50 mg (Dose Escalation Period 1) + MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) + MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Apr 1, 2015 → Feb 1, 2016
NCT ID
NCT02472535About MBX-8025 50 mg (Dose Escalation Period 1) + MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) + MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)
MBX-8025 50 mg (Dose Escalation Period 1) + MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) + MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) is a phase 2 stage product being developed by Gilead Sciences for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02472535. Target conditions include Homozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02472535 | Phase 2 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia